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Abstract The 31 kDa membrane protein stomatin was meta-
bolically labeled with tritiated palmitic acid in the human
amniotic cell line UAC and immunoprecipitated. We show that
the incorporated palmitate is sensitive to hydroxylamine,
indicating the binding to cysteine residues. Stomatin contains
three cysteines. By expressing a myc-tagged stomatin and
substituting the three cysteines by serine, individually or in
combination, we demonstrate that Cys-29 is the predominant site
of palmitoylation and that Cys-86 accounts for the remaining
palmitate labeling. Disruption of Cys-52 alone does not show any
detectable reduction of palmitic acid incorporation. Given the
organization of stomatin into homo-oligomers, the presence of
multiple palmitate chains is likely to increase greatly the affinity
of these oligomers for the membrane and perhaps particular lipid
domains within it.
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1. Introduction
The integral membrane protein stomatin was ¢rst recog-
nized as an important component of the erythrocyte mem-
brane (band 7.2b). After its subsequent puri¢cation [1,2],
and the cloning of its cDNA [3,4], the primary structure re-
vealed a 29 amino acid hydrophobic stretch, the putative
membrane domain, preceded by a 24 residue highly charged
N-terminus and followed by the C-terminal part containing
the majority of the 287 residues. Both N- and C-terminal
portions of the molecule are thought to be exposed at the
cytoplasmic face of the lipid bilayer [2,5]. Stomatin expression
is not restricted to red cells and can be detected in many
di¡erent tissues and cell lines [2,4,6,7].
Since our ¢nding of the 4^6-fold up-regulation of stomatin
in the human amniotic cell line UAC after treatment with
interleukin-6 (IL-6) and dexamethasone [8], we have been us-
ing this model to characterize the cellular localization as well
as some structural aspects of this protein. We have shown that
stomatin is concentrated in plasma membrane protrusions and
actin rich structures in UAC cells [9]. It is also present in
abundance in a population of juxta-nuclear vesicles. We then
demonstrated that the macromolecular organization of stoma-
tin is homo-oligomeric. Large oligomeric complexes of stoma-
tin can be extracted from cellular membranes using the non-
ionic detergent Triton X-100; nevertheless, a signi¢cant pro-
portion of the protein remains connected to the cytoskeleton
[10]. The complexes have an approximate size of 300 kDa
(9^12 monomers). As two C-terminally truncated forms
of stomatin are not incorporated into the complexes, it seems
likely that the C-terminus of the protein is involved in their
formation.
The presence of high order oligomers of stomatin on the
cytoplasmic side of plasma membrane folds, its partial asso-
ciation with the cytoskeleton as well as its co-localization with
cortical actin micro¢laments strongly point to a structural role
and suggest that stomatin can have an in£uence on the cort-
ical morphogenesis in UAC cells and perhaps other cells.
An important feature of stomatin is the presence of three
cysteine residues in positions 29, 52 and 86. Two of the res-
idues (Cys-29 and Cys-52) reside at the start and end of the
membrane domain whilst the third cysteine (Cys-86) is located
in a region characterized by a stretch of non-polar amino
acids. The proximity of these residues to the plasma mem-
brane makes them possible candidates for palmitoylation by
thioester linkage. This important post-translational lipid mod-
i¢cation occurs alone or in combination with other acylation
types on di¡erent integral and peripheral membrane proteins.
Examples are found, among others, in membrane receptors, K
subunits of heterotrimeric G proteins, small GTPases, and
non-receptor tyrosine kinases [11^13]. Palmitoylation confers
greater membrane a⁄nity, but can also a¡ect a protein func-
tionally or in£uence its interaction with other proteins and
speci¢c membrane domains.
In this report, we show that stomatin is palmitoylated in
UAC cells and that this acylation occurs by thioester linkage
on cysteine residues. Analysis of the palmitoylation sites by
directed mutagenesis of the three cysteines indicates that Cys-
29, located near the N-terminal end of the membrane domain,
is the major site of palmitoylation on stomatin whereas Cys-
86 contains all or most of the remaining palmitic acid.
2. Materials and methods
2.1. Reagents
The monoclonal antibody GARP 50, used directly from hybridoma
supernatant, speci¢cally recognizes stomatin and has been described
previously [2,9,10]. Hydroxylamine and anti-mouse agarose were from
Sigma. Palmitic acid [9,10-3H(N)] was purchased from American Ra-
diolabeled Chemicals, Inc. (St. Louis, MO, USA).
2.2. Cell culture
UAC cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
(BioWhittaker, Belgium) supplemented with 10% fetal calf serum (Life
Technologies, Inc.). To induce maximal expression of stomatin, cells
were grown to con£uence and treated for 24 h with 200 U/ml IL-6
and 0.1 WM dexamethasone as described [8].
2.3. DNA mutagenesis and cell transfections
To express recombinant stomatin in UAC cells, we used the eukary-
otic expression vector pEF-Puro.PL3 modi¢ed to allow fusion of sto-
matin with the myc-tag epitope at the C-terminus, as described pre-
viously [10], with the exception that only one copy of the myc epitope
was added in this study. From this construct, an EcoRI-NotI fragment
containing the stomatin-myc fusion was inserted into the vector
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pcDNA3 (Invitrogen). This latter plasmid was used to generate Cys to
Ser (TGC to AGC) mutations at positions 29, 52 and 86 of the
stomatin amino acid sequence. This was accomplished by overlap
extension using complementary oligonucleotides carrying the desired
mutations and T7 and SP6 primers £anking the multiple cloning site
of pcDNA3. All mutations were checked by dideoxy sequencing. Vec-
tors containing the single mutants were used as templates to generate
double mutants and one of those served to produce the triple mutant.
Constructs in pcDNA3 were transfected transiently in UAC cells (Pro-
Fection Mammalian Expression System, Promega) to verify expres-
sion of the respective proteins by immuno£uorescence using the anti-
myc antibody (Boehringer Mannheim). Subsequently, for each indi-
vidual construct, a SpeI-EcoRV fragment comprising the mutagenized
stomatin was subcloned into pEF-Puro.PL3. The resulting vectors
were used to generate stable transfectants in UAC cells as described
[10].
2.4. Palmitate labeling and immunoprecipitations
For metabolic labeling with radioactive palmitic acid, cells were
grown to con£uence in 10 cm petri dishes. They were rinsed twice
with serum-free medium and incubated for 4 h in 5 ml of serum-free
medium containing 300 WCi of tritiated palmitate. After incubation,
cells were rinsed two times with PBS, lysed in 1 ml of TNET (20 mM
Tris-HCl, pH 8, 150 mM NaCl, 5 mM EDTA and 1% Triton X-100)
containing 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml leupeptin,
10 Wg/ml aprotinin, 1 Wg/ml pepstatin and 5% fetal calf serum. After
removal of insoluble material by centrifugation, lysates were incu-
bated successively with anti-stomatin antibody and goat anti-mouse
IgG agarose. Immune complexes were recovered by centrifugation
and washed four times with TNET. They were then eluted in Laemmli
sample bu¡er (without L-mercaptoethanol) and separated by SDS-
PAGE. Gels were treated with a £uorographic agent according to
the manufacturer’s instructions (Amplify, Amersham), dried and ex-
posed on Kodak BioMax MR ¢lms. Exposure times ranged from 10^
20 days (Fig. 1) to 2 months (Figs. 2 and 3). Scanning densitometry of
autoradiographs was performed on a Personal Densitometer (Molec-
ular Dynamics) using the program ImageQuant.
2.5. Hydroxylamine treatment
IL-6 and dexamethasone treated UAC cells were metabolically la-
beled with tritiated palmitate and stomatin was immunoprecipitated.
Half of the precipitate was rotated overnight in a solution of 1 M
hydroxylamine, pH 7.2, while the other half was incubated in 1 M
Tris-HCl, pH 7.2. Subsequently, the solutions were discarded. Pro-
teins were eluted in Laemmli sample bu¡er and separated by SDS-
PAGE. Labeling of stomatin was visualized by £uorography.
2.6. Immunoblotting
Extracts of the di¡erent clones, obtained concomitantly by the same
procedure as for immunoprecipitation, were analyzed by Western
blotting as described [10], using anti-stomatin antibody GARP 50,
anti-mouse horseradish peroxidase conjugate (Promega) and detection
by chemiluminescence (SuperSignal Chemiluminescent Substrate,
Pierce).
3. Results and discussion
3.1. Stomatin is palmitoylated by thioester linkage
To investigate the possibility that stomatin is palmitoylated
in UAC cells, we labeled the cells metabolically with tritiated
palmitic acid and immunoprecipitated stomatin after lysis in a
bu¡er containing 1% Triton X-100. This detergent has been
shown to solubilize 70^80% of stomatin from these cells [10].
Immunoprecipitates were analysed by SDS-PAGE and £uo-
rography. Fig. 1A shows that immunoprecipitated stomatin
has incorporated palmitate. In IL-6 and dexamethasone
treated cells, there is an increase of labeling corresponding
to the reported up-regulation of stomatin following this treat-
ment [8]. This last experiment indicates that the degree of
palmitoylation of the protein remains constant even when
its expression is increased.
Next, we examined the sensitivity of stomatin-bound palmi-
Fig. 1. Palmitoylation of stomatin on one or more cysteine residues.
A: UAC cells were treated with IL-6 and dexamethasone or left un-
treated as indicated. They were metabolically labeled with
[3H]palmitic acid before immunoprecipitation of stomatin. B:
[3H]Palmitate labeled stomatin was immunoprecipitated from UAC
cells. Half of the precipitate was treated with 1 M Tris-HCl pH 7.2
(Tris) and the other half was treated with 1 M hydroxylamine pH
7.2 (Hydroxylamine).
Fig. 2. Cys-29 is the major palmitoylation site on stomatin. Upper
panel: UAC cells stably expressing stomatin C-terminally fused to a
myc tag (STmyc), or the mutated forms Cys-29-Ser, Cys-52-Ser and
Cys-86-Ser of this construct, as indicated, were labeled with tritiated
palmitic acid and subjected to immunoprecipitation using the anti-
stomatin antibody. Note that cells were not treated with IL-6 and
dexamethasone to avoid a too strong signal from endogenous sto-
matin. The gel was exposed for 2 months in order to visualize
weakly labeled bands. Arrows indicate the positions of endogenous
stomatin (Endogen.) or myc-tagged stomatin and mutants (Re-
comb.). Lower panel: At the same time, extracts of the di¡erent
clones were analyzed by immunoblotting using the anti-stomatin
antibody. To see better the expression of Cys-86-Ser, an immuno-
blot was performed with more protein (lower panel, inset).
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tate to neutral hydroxylamine treatment. Fig. 1B shows that
the incorporated palmitic acid is almost completely released
by incubating the immunoprecipitate in 1 M hydroxylamine
pH 7.2, as compared to 1 M Tris at the same pH. This result
demonstrates that stomatin undergoes acylation through thio-
ester linkage involving one or more cysteine residues.
3.2. Cys-29 is the major palmitoylation site
In order to determine which of the three cysteines at posi-
tions 29, 52 and 86 is palmitoylated, we substituted each cys-
teine with serine, either individually, two at a time or all three
together, and expressed these mutated stomatin molecules in
UAC cells. The expressed proteins were fused at the C-termi-
nus to a myc epitope allowing us to distinguish between re-
combinant and endogenous stomatin by SDS-PAGE and also
making possible the examination of cellular localization by
immuno£uorescence. We have shown previously that the
myc-tagged stomatin displays immuno£uorescence patterns
identical to the endogenous protein and can e⁄ciently incor-
porate into stomatin oligomers [10]. In transient transfections
followed by immuno£uorescent staining using the anti-myc
antibody, all the di¡erent mutants were found to be localized
as stomatin (not shown). However, the triple Cys-29,52,86-Ser
mutant was expressed in much fewer cells and was more di⁄-
cult to detect, probably because of a greater instability of the
molecule. For palmitic acid labeling experiments, we per-
formed stable transfections of the di¡erent constructs, because
stable transfections allow recombinant proteins to be more
evenly expressed among cells of the same culture. First, clones
expressing each mutated stomatin were isolated and analysed
by Western blotting using the anti-stomatin antibody (Figs. 2
and 3). For Cys-86-Ser, Cys-52,86-Ser and Cys-29,86-Ser, we
could only obtain low expression levels compared to the other
constructs. We did not obtain clones stably expressing the
Cys-29,52,86-Ser mutant. We then metabolically labeled cells
expressing wild-type, Cys-29-Ser, Cys-52-Ser and Cys-86-Ser
epitope-tagged stomatin with palmitate and lysates were im-
munoprecipitated using the anti-stomatin antibody. For each
clone, the endogenous stomatin was used as a control of label-
ing e⁄ciency (Fig. 2). The data show that, while the palmi-
toylation of myc-tagged stomatin is as e⁄cient as the endog-
enous protein, labeling of Cys-29-Ser is strongly reduced (as
compared to the expression level assessed with the immuno-
blot). Cys-52-Ser does not display any apparent reduction of
palmitoylation and Cys-86-Ser palmitoylation is only slightly
reduced, relative to the expression level. Quantitative analysis
of the autoradiographs by scanning densitometry (Table 1)
shows that the radioactivity associated with Cys-29 comprises
70^85% of the total labeling. It also indicates that the remain-
ing palmitoylation (15^30%) occurs on Cys-86. To con¢rm
these data, we performed the same experiment using the dou-
ble mutants (Fig. 3 and Table 1). The strong decrease of
labeling observed for Cys-29,52-Ser is in agreement with the
result obtained for Cys-29-Ser. For Cys-52,86-Ser, the protein
is still clearly radiolabeled despite its low expression. Finally,
no radioactive band can be observed for Cys-29,86-Ser even
after a very long exposure of the gel. Because of the back-
ground in Fig. 3, upper panel, third lane, we performed an
additional palmitate labeling of Cys-29,86-Ser. The result con-
¢rmed that this mutant is not palmitoylated (not shown). In
conclusion, experiments presented in Figs. 2 and 3 and sum-
marized in Table 1 demonstrate that Cys-29 is the major site
of palmitoylation of stomatin (70^85%) and that the remain-
ing acylation occurs on Cys-86.
Palmitoylation of stomatin is not restricted to UAC cells, as
it was also reported for band 7.2b in erythrocytes [1]. A pre-
requisite for this modi¢cation is the proximity of a cysteine
residue to the membrane. This is the case for Cys-29 in sto-
matin and probably also for Cys-86, which is preceded by a
short hydrophobic stretch. The possibility has been raised that
this region constitutes a second membrane spanning domain
in UNC-1, a protein very similar to stomatin in Caenorhabdi-
tis elegans [14]. Our ¢nding that Cys-52 might be completely
devoid of palmitoylation does not contradict this model, but
digestion studies performed on intact erythrocytes exclude in
principle an extracellular part for stomatin [2]. At any rate,
even a partial palmitoylation of Cys-86 assigns this region to
the membrane vicinity while palmitoylation of Cys-29 con-
¢rms, if needed, that the N-terminus of stomatin is intra-cy-
toplasmic [5].
Fig. 3. Stomatin Cys-29,86-Ser is not palmitoylated. Upper panel:
UAC cells expressing the double mutants Cys-29,52-Ser, Cys-52,86-
Ser and Cys-29,86-Ser were metabolically labeled with tritiated pal-
mitic acid and immunoprecipitations were performed using anti-sto-
matin antibody. Arrows indicate the positions of endogenous stoma-
tin (Endogen.) or myc-tagged stomatin and mutants (Recomb.).
Lower panel: Extracts from the same cells were analyzed by immu-
noblotting using anti-stomatin antibody. The inset shows an immu-
noblot of the Cys-29,86-Ser extract, with more protein loaded on
the gel to show better the presence of the recombinant protein.
Table 1
Quantitative analysis of stomatin palmitoylation
WB AR AR/WB
STmyc 95 101 106
Cys-29-Ser 74 11 15
Cys-52-Ser 74 82 111
Cys-86-Ser 22 15 68
Cys-29,52-Ser 59 9 15
Cys-52,86-Ser 30 20 67
Cys-29,86-Ser 17 0 0
Autoradiographs and Western blots shown in Figs. 2 and 3 were
analyzed by scanning densitometry. WB, AR: percentages of expres-
sion (WB) or of palmitoylation (AR) of the myc-tagged stomatin
(or the di¡erent mutants) as compared to endogenous stomatin.
AR/WB: values obtained for the autoradiographs are given as a
percentage ( þ 10%) of the values obtained for the Western blots.
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We have already compared stomatin to caveolin [10]. Both
proteins are anchored to the cytosolic part of the membrane
by a ‘‘hairpin loop’’ and also build up high order oligomers
[10,15,16]. The palmitoylation of stomatin resembles caveolin
in that it occurs on more than one cysteine and the major
acylation site (Cys-133 in caveolin) is located at one end of
the membrane domain, on the side of the shorter cytoplasmic
stretch [17]. Interestingly, both Cys-29 in stomatin and Cys-
133 in caveolin are £anked by a proline residue. This is also
the case for Cys-86 of stomatin. That an adjacent proline and
a hydrophobic environment might be favorable to trigger pal-
mitate addition to a cysteine is a possibility which was sug-
gested for the Rh protein [18].
The organization of stomatin into oligomers does not allow
us to examine whether abolition of palmitoylation has an
impact on the protein a⁄nity for the membrane, because
oligomers also contain the endogenous palmitoylated protein.
This can explain why all the mutants were found to have a
correct cellular localization. Nevertheless, some cysteine resi-
dues appear to be important for stomatin stability, without
correlation with the palmitoylation level. This seems to be the
case for Cys-86 because proteins mutated at this residue could
be expressed stably only in low amounts, and also for Cys-52,
as the triple mutant could not be stably expressed, in contrast
to Cys-29,86-Ser. These low or undetectable expression levels
are likely to be a consequence of instability of the proteins at
early stages of biosynthesis.
Although experiments described in this paper do not allow
us to deduce the stoichiometry of stomatin palmitoylation,
one can assume that the organization of this protein into
stable oligomers covalently linked to several palmitate chains
creates a relatively high concentration of this lipid in the
plasma membrane. In an interesting discussion on caveolin,
Brown and London [19] propose that this e¡ect could be one
reason why this protein has privileged interactions with deter-
gent insoluble lipid domains [20]. Our preliminary data indi-
cate that stomatin is partially present in detergent resistant
domains in UAC cells along with GPI-anchored proteins
with which it co-localizes in immuno£uorescence (L. Snyers,
unpublished results). This property is likely to represent one
rationale for the covalent attachment of palmitic acid to sto-
matin.
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